Mammoth in-licenses CRISPR-Cas14 IP

Mammoth exclusively licensed IP covering one of the newest families of CRISPR enzymes, Cas14, from the University of California Berkeley. The new license adds a third group of CRISPR enzymes to the diagnostics company's toolbox.

While the IP landscape covering CRISPR-Cas9 for therapeutic applications is becoming increasingly complex following the conclusion of the interference case between a Regents of the University of California group and the Broad Institute of MIT and Harvard, the IP covering CRISPR-associated protein 14 (Cas14) and other CRISPR enzymes is not involved in that dispute...